Patients with diabetes and hypertension
Conditions
Interventions
In the thiazolidine derivatives group, thiazolidine derivatives will be prescribed as per specifications attached.
In sulfonylurea hypoglycemic agent, the agent will be prescribed as per specification
Sponsors
HuBit genomix, Inc.
National Cerebral and Cardiovascular Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patient with both diabetes and essential hypertension or patient undergoing treatment of antihypertensive agent who is newly taking diabetic medicine
Exclusion criteria
Exclusion criteria: 1) History of cardiac failure 2) Diagnosis of Cardiovascular disturbance and/or cerebrovascular disease within 6 months 3) Secondary hypertension 4) Type I diabetes 5) Diagnosis and/or treatment of cancer within 5 years 6) Renal dysfunction 7) Liver dysfunction 8) History of side effects of TDZ or ARB 9) No current or past history of psychiatric disorders 10) Pregnant women or lactating mothers 11) Participating another clinical investigation within 3 months 12) Patients judged by the investigator to be unfit to be enrolled into the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary end-point is time from randomization to first occurrence of any of the events in the following composite: 1. Cardiovascular disturbance 2. Cerebrovascular disease 3. Renal failure 4. Administration of dialysis treatment 5. Cardiac mortality 6. Cerebrovascular mortality | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end-point is time from randomization to first occurrence of any of the events in the following composite: 1. All-cause mortality 2. Cardiac depression and impairing renal function 3. Progression of diabetes 4. Progression of hypertension | — |
Countries
Japan
Contacts
Public ContactYasuhiko Koezuka
HuBit genomix, Inc. Research & Development Department
Outcome results
None listed